# Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis

> **NCT02534636** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 140 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** BMS-986165
- **DRUG:** Interferon alpha-2a recombinant
- **DRUG:** Famotidine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02534636
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2016-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02534636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02534636, "Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02534636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*